Background: Current guidelines recommend against thyrotropin (TSH) suppression in low-
risk differentiated thyroid cancer patients; however, physician practices remain …

The ideal therapy for differentiated thyroid cancer is uncertain. Although thyroid hormone
treatment is pivotal, the degree of thyrotropin (TSH) suppression that is required to prevent …

Context: TSH suppression therapy has been used to decrease thyroid cancer recurrence.
However, validation of effects through studies providing a high level of evidence has been …

Objective: Guidelines recommend thyroid-stimulating hormone (TSH) suppression before
the first response to treatment assessment in papillary thyroid cancer (PTC) patients. The …

Background: Long-term management of intermediate-and high-risk differentiated thyroid
cancer (DTC) involves thyrotropin (TSH) suppression with thyroid hormone to prevent …

Importance Suppression of thyrotropin (often referred to asthyroid-stimulating hormone,
orTSH) with levothyroxine used in management of intermediate-and high-risk differentiated …

BACKGROUND. Long-term thyroid hormone (TH) therapy aiming at the suppression of
serum thyrotropin (TSH) has been traditionally used in the management of well differentiated …

Published guidelines on the treatment of thyroid carcinoma support TSH suppressive
therapy as the standard of care for long-term follow-up after initial surgery and sequential …

Background Postoperative thyroid stimulating hormone (TSH) suppression therapy is
recommended for patients with intermediate-and high-risk differentiated thyroid cancer to …

Background: Thyrotropin (TSH) suppression has improved the clinical outcomes of patients
with differentiated thyroid cancer (DTC). However, the efficacy of TSH suppressive therapy …